Antibe
Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE, OTCQX:
ATBPF) today announced that they have, subject to approval by securities
regulators, entered into an Investor Relations Consulting Agreement with
Stonegate Capital Partners Inc. (“Stonegate”) based in Dallas, Texas.
Under the terms of the agreement Stonegate will receive a monthly fee of
$4,000 for a minimum of 6 months and will be granted 24,000 options.
Such options will vest quarterly starting on the date of the grant, will
be exercisable at a price of $0.52, and will expire October 31, 2017.
About Stonegate Capital Partners
Stonegate Capital Partners is an investment banking and corporate
advisory firm dedicated to serving the specialized needs of small-cap
public companies. They provide research, sales and trading, corporate
finance, strategic advisory and corporate advisor services to a select
group of clients. They work with leading institutional investors in the
U.S. and Europe who seek high quality investment opportunities in the
small cap marketplace.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s
technology involves linking a hydrogen sulfide-releasing molecule to an
existing drug to produce a patented, improved medicine. Antibe’s lead
drug ATB-346 targets the global need for a safer non-steroidal
anti-inflammatory drug (NSAID) for chronic pain and inflammation.
ATB-352, the second drug in Antibe’s pipeline, targets the urgent global
need for a safer analgesic for severe acute pain.
www.antibethera.com
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
Important
Note on Forward Looking Statements
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20141216005158r1&sid=ntxv4&distro=nx&lang=en)
Copyright Business Wire 2014